<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The case of a patient with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> who received combination exenatide-<z:chebi fb="0" ids="40237">sitagliptin</z:chebi> with glipizide is reported </plain></SENT>
<SENT sid="1" pm="."><plain>SUMMARY: A 55-year-old, 204-lb Caucasian woman arrived at a clinic with <z:hpo ids='HP_0001959'>polydipsia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Her blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration was 450 mg/dL and her glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA(1c)) value was 13.4% </plain></SENT>
<SENT sid="3" pm="."><plain>She was diagnosed with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and started on <z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> 500 mg orally twice daily </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> was later discontinued due to elevated liver function test values </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> 100 mg daily was substituted, and glipizide was later added and its dosage adjusted over the next several months </plain></SENT>
<SENT sid="6" pm="."><plain>After six months, her HbA(1c) value had decreased to 9.3% and she had gained 14 lb </plain></SENT>
<SENT sid="7" pm="."><plain>Exenatide was then added to her regimen, and the dosage was adjusted to 10 Î¼g subcutaneously twice daily </plain></SENT>
<SENT sid="8" pm="."><plain>Two months after the initiation of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, glipizide, and exenatide, the patient had lost 10 lb, reported significant improvements in self-monitored blood <z:chebi fb="105" ids="17234">glucose</z:chebi> readings, and required a reduction in glipizide dosage despite no reported therapeutic lifestyle changes </plain></SENT>
<SENT sid="9" pm="."><plain>Seven months after the initiation of exenatide, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, and glipizide, her HbA(1c) value was 7.4% </plain></SENT>
<SENT sid="10" pm="."><plain>Triple therapy resulted in a total HbA(1c) value reduction of 1.9%, a <z:hpo ids='HP_0001824'>weight loss</z:hpo> of 11 lb, and normalized liver function test values </plain></SENT>
<SENT sid="11" pm="."><plain>The patient's <z:mp ids='MP_0002842'>high blood pressure</z:mp> was treated with <z:chebi fb="0" ids="6541">losartan</z:chebi> and remained at goal throughout the duration of this report </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: In a patient with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, the addition of the incretin mimetic exenatide and the dipeptidyl peptidase-4 inhibitor <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> to glipizide therapy appeared effective and safe </plain></SENT>
</text></document>